Novosom Licenses Next-Generation CD40 Targets From Isis
This article was originally published in The Pink Sheet Daily
Executive Summary
Novosom plans to use Isis’ antisense oligonucleotides targeting CD40 with its proprietary Smarticles technology to enhance delivery.
You may also be interested in...
Genzyme, Isis Retool Mipomersen Deal
Firms confident, but some analysts skeptical about what might be required for approval of lipid antisense drug.
Isis: Pondering Platform Power
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.